To those tracking the first product liability trial accusing Merck's osteoporosis drug Fosamax of causing debilitating jaw bone deterioration, it should come as no surprise that a mistrial was declared on Friday. But the lead plaintiffs lawyer's view of the eight-member jury's failure to reach a verdict may raise some eyebrows.
Fosamax Plaintiffs Lawyer: Mistrial a 'Shock' to Merck
The American Lawyer
September 14, 2009